Intravenous Tocilizumab (IV tocilizumab) coverage
Customize your policy alerts
Sign up for Bluecross Idaho Policy 5.01.502 alerts
Get alerted when Policy 5.01.502 changes without checking for updates manually.
Monitor payer policy activity
Defines medical-benefit coverage, clinical criteria, and prior-authorization expectations for intravenous tocilizumab (including Actemra and listed biosimilars) for specified indications; applies to Blue Cross of Idaho members subject to their member-specific benefit plan.
Blue Cross of Idaho adopted changes effective 01/01/2026, including a policy statement about subcutaneous formulation and clarifications related to tuberculosis screening.
New policy added to prescription drug section.
tocilizumab is to be filled under the pharmacy benefit.
Coverage Criteria
inv-01: General medical necessity
Intravenous tocilizumab may be considered medically necessary when ALL of the general requirements below are met and ONE of the indication-specific criteria is satisfied.
inv-02: Rheumatoid Arthritis (RA) - Initial Therapy
Rheumatoid Arthritis (RA) - covered when ALL of the following are met:
inv-03: Polyarticular Juvenile Idiopathic Arthritis (PJIA) - Initial Therapy
Polyarticular Juvenile Idiopathic Arthritis (PJIA) - covered when ALL of the following are met:
inv-04: Systemic Juvenile Idiopathic Arthritis (SJIA) - Initial Therapy
Systemic Juvenile Idiopathic Arthritis (SJIA) - covered when ALL of the following are met:
inv-05: Giant Cell Arteritis (GCA) - Initial Therapy
Giant Cell Arteritis (GCA) - covered when ALL of the following are met:
inv-06: CAR T–cell induced Cytokine Release Syndrome (CRS) - Initial/Acute Therapy
Cytokine Release Syndrome (CRS) - covered when ALL of the following are met:
inv-07: Castleman's Disease (unicentric or multicentric)
Castleman's Disease - covered when ALL of the following are met:
inv-08: Covered indications and safety criteria
Coverage aligns with FDA-approved indications and recognized off-label uses per NCCN where specified.
See regulatory status
See off‑label uses
See safety and monitoring guidance
IV tocilizumab is investigational for any indication not specifically listed in this policy. The policy enumerates covered uses (including Castleman’s disease, CAR T–cell induced CRS, RA, PJIA, SJIA, and GCA); any request for intravenous tocilizumab outside those listed indications is considered investigational and unsupported by this document.
Concurrent use of IV tocilizumab with other biologic disease‑modifying antirheumatic drugs (DMARDs) or biologic agents (for example, TNF antagonists, IL‑1 receptor antagonists, anti‑CD20 monoclonal antibodies, or selective costimulation modulators) should be avoided due to the potential for increased immunosuppression and infection risk. Tocilizumab may be used as monotherapy or with nonbiologic DMARDs (e.g., methotrexate, hydroxychloroquine, leflunomide, azathioprine, cyclosporine) per the policy.
This policy clarifies benefit routing and screening requirements: tocilizumab is to be filled under the pharmacy benefit, and administration/billing guidance should follow the appropriate benefit and place‑of‑service coding. Prior authorization is required for IV tocilizumab to ensure appropriate use. In addition, documentation of tuberculosis screening is required — TB evaluation must be completed and documented as indicated by the policy prior to initiation (see screening clarifications in the policy record).
For CAR T–cell–induced cytokine release syndrome (CRS), IV tocilizumab is limited to acute treatment only. Continuation or renewal requests for CRS are not allowed, and treatment for CRS should not exceed a total of four doses (dosing per the CRS criteria with up to three additional doses given ≥8 hours apart as specified).
Safety and effectiveness of tocilizumab have not been established in pediatric patients for conditions other than PJIA, SJIA, or CAR T cell–induced CRS. Specifically, use in children under age 2 has not been studied and is not supported by this policy.
Initial Therapy Criteria
inv-39: Initial therapy requirements
Initial therapy is covered when the general requirements are met and the relevant indication-specific initiation criteria above are satisfied.
inv-40: Initiation
Initiation follows FDA‑labeled indications and recognized compendium uses; ensure appropriate baseline screening and monitoring.
Continuation of Treatment
inv-41: Continuation of Treatment
Continuation or renewal requests for IV tocilizumab may be considered medically necessary when ALL of the following criteria are met:
inv-42: Ongoing therapy requirements
Ongoing therapy should include regular monitoring and infection surveillance.
See monitoring guidance
Step Therapy and Prior Treatments
| Prior therapy required | Required trial duration / details |
|---|---|
| At least two (2) covered alternative products for the requested indication (or documented contraindication/intolerance to all available covered alternatives) | |
| Generally requires inadequate therapeutic response after specified trials per indication (see individual indications). For RA: inadequate response to at least a 3‑month trial of methotrexate at adequate dosing (e.g., titrated to 20 mg/week) or if methotrexate intolerant/contraindicated, inadequate response/intolerance/contraindication to a 3‑month trial of ≥1 other conventional DMARD | |
| For PJIA: inadequate response, intolerance, or contraindication to a 3‑month trial of ≥1 conventional DMARD | |
| For SJIA: inadequate response to at least a 2‑week trial of corticosteroids OR inadequate response to at least a 3‑month trial of methotrexate or leflunomide | |
| For GCA: inadequate response, intolerance, or contraindication to at least a 3‑month trial of corticosteroids | |
| For CAR T cell–induced CRS: treatment is for severe or life‑threatening CRS per FDA dosing; CRS use is acute (limited to ≤4 total doses) rather than a standard step‑therapy sequence |
| Documentation element | Notes / policy text |
|---|---|
| Evidence of prior DMARD failure or intolerance | |
| RA-specific: documentation of inadequate response to at least a 3‑month trial of methotrexate at adequate dosing (e.g., titrated to 20 mg/week) OR if methotrexate is contraindicated/intolerant, inadequate response/intolerance/contraindication to a 3‑month trial of ≥1 other conventional DMARD (see Appendix lists) | |
| Record of contraindication or intolerance to alternatives when fewer than two covered alternatives are available | |
| Baseline infection screening and management documentation: TB screening within 6 months and HBV evaluation or evidence of treatment when indicated; absence of active infection must be documented |
| Appendix DMARD | Class / example agents |
|---|---|
| Conventional DMARDs | |
| Examples: azathioprine; cyclophosphamide; cyclosporine; hydroxychloroquine; leflunomide; methotrexate; mycophenolate; sulfasalazine | |
| Biologic DMARDs | |
| Examples: abatacept; adalimumab; anakinra; brodalumab; certolizumab; etanercept; golimumab; guselkumab; infliximab; ixekizumab; risankizumab; rituximab; sarilumab; secukinumab; spesolimab; tildrakizumab; tocilizumab (Actemra); ustekinumab; vedolizumab | |
| Targeted synthetic DMARDs | |
| Listed in appendix as targeted synthetic disease‑modifying agents (see Appendix 1 for full list) |
Coding and Billing
| Actemra IV vial sizes referenced (80 mg, 200 mg, 400 mg) | Prior-approval quantity entries reference 80 mg, 200 mg, and 400 mg single-dose vials; example: 8 single-dose vials per lifetime for CRS |
| D89.810 | Acute graft-versus-host disease. |
| D89.831 - D89.839 | Cytokine release syndrome. |
| M05.01X- M05.09 | Felty's syndrome code range. |
| M05.09 M05.21X- M05.29 | Rheumatoid vasculitis with rheumatoid arthritis code range. |
| M05.30X- M05.39 | Rheumatoid heart disease with rheumatoid arthritis code range. |
| M05.4X- M05.49 | Rheumatoid myopathy with rheumatoid arthritis code range. |
| M06.00 - M06.0A | Rheumatoid arthritis without rheumatoid factor code range. |
| M06.1 | Adult-onset Still's disease / related codes referenced. |
| M08.00- M08.2A | Juvenile rheumatoid arthritis code ranges. |
| M31.5 - M31.6 | Giant cell arteritis code range. |
| No codes listed |
Provider Actions and Requirements
Prior authorization applies with specific quantity and vial limits
Prior authorization with quantity limits applies for IV tocilizumab; the policy lists indication-specific vial/quantity rules (e.g., Actemra IV single-dose vials in 80 mg, 200 mg, and 400 mg strengths and an example limit of 8 single‑dose vials per lifetime for CRS).
- Actemra IV single‑dose vial strengths referenced: 80 mg, 200 mg, 400 mg.
- Example quantity limit for CRS: 8 single‑dose vials per lifetime.
Prior authorization required for IV tocilizumab
Prior authorization is required for intravenous tocilizumab (including listed biosimilars) to ensure safe, clinically appropriate, and cost‑effective use as described in the policy.
Prior authorization expectation implied by policy adoption and routing
The policy is a prescription drug policy that requires prior authorization for IV tocilizumab and clarifies benefit routing and management under the medical/pharmacy benefits; requests should be submitted consistent with the policy's authorization process.
Step therapy: document inadequate response to required prior therapies
Step‑therapy requirements mandate documented inadequate response or intolerance to specified prior therapies before initiating IV tocilizumab — generally failure of required prior agents (e.g., DMARDs or corticosteroids) for the durations specified by indication.
- RA: inadequate response to a 3‑month trial of methotrexate (or intolerance/contraindication plus failure of ≥1 other conventional DMARD).
- SJIA: inadequate response to a 2‑week corticosteroid trial or a 3‑month methotrexate/leflunomide trial.
- PJIA: inadequate response/intolerance/contraindication to a 3‑month trial of ≥1 conventional DMARD.
RA requires prior DMARD trial or documented intolerance
For rheumatoid arthritis, the policy references prior inadequate response to DMARD therapy (e.g., inadequate response to a 3‑month trial of methotrexate or failure of other conventional DMARDs when methotrexate is not tolerated).
DMARDs listed for sequencing / step therapy
Appendix‑listed DMARDs (conventional, biologic, and targeted synthetic agents) are referenced for sequencing and may be used to document prior therapy failure or intolerance when applying step therapy requirements.
- Conventional DMARD examples: methotrexate, leflunomide, hydroxychloroquine, sulfasalazine, azathioprine, cyclosporine, mycophenolate, azathioprine.
- Biologic DMARD examples: abatacept, adalimumab, anakinra, infliximab, rituximab, sarilumab, tocilizumab, etc.
- Targeted synthetic DMARDs listed in Appendix 1 (see policy appendices).
Required documentation for authorization
Authorization requests must include documentation of prior inadequate therapeutic response (or documented contraindication/intolerance), TB screening within 6 months, and HBV evaluation or treatment status as applicable.
- Evidence of trials and durations for prior therapies (e.g., methotrexate 3 months at adequate dosing).
- TB screening within 6 months prior to initiation or documentation of prior treated latent TB.
- HBV risk assessment and documentation that HBV has been ruled out or treatment initiated when applicable.
Documentation specifics: infection/TB, hepatic status, and indication justification
Include infection/TB screening results, baseline hepatic status, and clinical justification for the requested indication (FDA‑approved or NCCN compendium off‑label use) when submitting an authorization.
- Results of latent TB testing and any TB treatment plan if latent TB is present.
- Liver function status and documentation excluding active hepatic disease or positive HBV/HCV without management.
- Statement of FDA‑labeled indication or NCCN‑supported off‑label indication and applicable dosing.
Document benefit routing and TB screening in the authorization record
Document the benefit routing (medical vs pharmacy) and tuberculosis screening steps in the authorization record; the policy history notes and clarifications about pharmacy benefit routing and TB screening should be reflected in documentation.
Triggers for denial if required screenings, safety, or dosing criteria are absent
Requests should be denied when required TB or HBV screening is missing, if there is an active infection, if tocilizumab is requested concurrently with another biologic/targeted DMARD, or when dosing/authorization requirements are not met.
- Missing TB or HBV screening or failure to start TB treatment when latent TB is present.
- Evidence of active infection or active hepatic disease (including unmanaged HBV/HCV).
- Concurrent use with other biologic DMARDs, targeted synthetic DMARDs, or immunomodulators.
- Requests exceeding the IV infusion dose cap (do not exceed 800 mg per infusion) or lacking required prior authorization.
Lack of prior authorization may lead to denial
Absence of prior authorization for IV tocilizumab may result in denial of coverage; prior authorization is required by this prescription drug policy.
Contraindications and safety exclusions to check before authorizing
The policy identifies contraindications and safety exclusions that should prompt denial or non‑coverage: active infection (including TB), active hepatic disease or hepatic impairment (including positive HBV/HCV), and use in patients under age 2 for non‑indicated pediatric conditions.
- Do not initiate in patients with active infections; interrupt therapy until infection is controlled.
- Treatment is not recommended in patients with active hepatic disease or hepatic impairment, including positive HBV/HCV without appropriate management.
- Safety and effectiveness not established in children under 2 years for most conditions.
Confirm benefit routing (pharmacy vs medical) to avoid coverage problems
Ensure to route the product correctly per benefit: the policy clarifies that tocilizumab is to be filled under the pharmacy benefit (where applicable) and IV administration is billed under the medical benefit; incorrect routing may create coverage issues.
- IV tocilizumab is billed under the medical benefit for infusion settings.
- Subcutaneous tocilizumab is filled under the pharmacy benefit and subject to pharmacy utilization management.
Quantity Limits and Site of Care
Site of Care and Benefit Routing
Bill IV tocilizumab under the medical benefit at appropriate infusion sites
Infusion of IV tocilizumab should be billed under the medical benefit and is appropriate in infusion center, hospital outpatient, or office settings per the policy's site‑of‑care guidance.
Follow medical‑benefit coding and place‑of‑service guidance for IV administration
Place‑of‑service and coding guidance indicate IV tocilizumab is billed under the medical benefit; use the HCPCS/ICD/CPT codes referenced in the policy for claims and site‑of‑service reporting.
Route dispensing of tocilizumab formulations under the pharmacy benefit when applicable
Tocilizumab products intended for outpatient dispensing (subcutaneous formulations) should be filled under the pharmacy benefit; the policy notes pharmacy benefit routing for some formulations.
Biosimilars and Therapeutic Equivalence
Actemra IV and listed biosimilars eligible when criteria met
Intravenous Actemra (tocilizumab) and the listed IV biosimilars (Tofidence, Tyenne) may be considered medically necessary when policy criteria are met.
Biosimilar billing code Q5133 (Tofidence) recognized
The policy lists HCPCS Q5133 for the biosimilar tocilizumab‑bavi (Tofidence) and treats it equivalently to the reference product for billing when criteria are satisfied.
- HCPCS Q5133 — Injection, tocilizumab‑bavi (Tofidence), biosimilar, 1 mg.
Background
Tocilizumab is an interleukin‑6 (IL‑6) receptor antagonist available in intravenous formulations (Actemra and listed biosimilars) used to treat multiple autoimmune and inflammatory conditions. The policy covers IV tocilizumab for specified FDA‑labeled indications — including adult rheumatoid arthritis, giant cell arteritis, systemic and polyarticular juvenile idiopathic arthritis — and for severe or life‑threatening CAR T cell–induced cytokine release syndrome. The document also references recognized off‑label uses (for example, Castleman’s disease per NCCN) and distinguishes IV (medical/pharmacy routing clarified) from subcutaneous formulations.
Definitions
Revision History
Blue Cross of Idaho adoption of policy changes became effective, including addition of a statement about subcutaneous formulation and clarifications to tuberculosis screening.
Policy replaced and changes adopted by Blue Cross of Idaho as noted for a future effective date of 2026-01-01.
New policy added to the prescription drug section (policy created and recorded in policy history).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.